Keyphrases
Breast Cancer Recurrence
100%
Phase II Clinical Trial
100%
Electrochemotherapy
100%
Clinical Examination
40%
Electric Pulse
40%
Symptom Relief
20%
Promising Treatment
20%
Further Treatment
20%
Patient-reported Symptoms
20%
Phase II Study
20%
Bleomycin
20%
Heavily Pretreated Patients
20%
Objective Response
20%
Difficult-to-treat
20%
Positron Emission Tomography-computed Tomography (PET-CT)
20%
Anticancer Treatment
20%
Exudates
20%
Treatment Alternatives
20%
Cell Membrane
20%
Lung Diffusing Capacity
20%
Treatment Options
20%
Bleeding
20%
Phase II Trial
20%
Cell Killing
20%
High Efficiency
20%
Membrane Permeable
20%
Tumor Cells
20%
Medicine and Dentistry
Recurrent Disease
100%
Clinical Trial
100%
Breast Cancer
100%
Pulse Rate
40%
Clinical Examination
40%
Neoplasm
20%
Bleomycin
20%
Positron Emission Tomography-Computed Tomography
20%
Lung Diffusion Capacity
20%
Exudate
20%
Venous Ulcer
20%
Antiinfective Agent
20%
Phase II Trials
20%
Side Effect
20%
Tumor Cell
20%
Cell Membrane
20%
Bleeding
20%
Biochemistry, Genetics and Molecular Biology
Clinical Trial
100%
Pulse Rate
100%
Positron Emission Tomography-Computed Tomography
50%
Bleomycin
50%
Cell Membrane
50%
Phase II Trials
50%
Tumor Volume
50%
Anticancer
50%
Lung Diffusion Capacity
50%
Pharmacology, Toxicology and Pharmaceutical Science
Recurrent Disease
100%
Clinical Trial
100%
Breast Cancer
100%
Neoplasm
40%
Exudate
20%
Bleomycin
20%
Phase II Trials
20%
Side Effect
20%
Antiinfective Agent
20%
Ulcer
20%
Bleeding
20%
Polyethylene Terephthalate
20%
Nursing and Health Professions
Breast Cancer
100%
Recurrent Disease
100%
Pulse Rate
40%
Clinical Examination
40%
Bleeding
20%
Tumor Volume
20%
Bleomycin
20%
Positron Emission Tomography-Computed Tomography
20%
Ulcer
20%
Side Effect
20%
Lung Diffusion Capacity
20%
Antiinfective Agent
20%
Neoplasm
20%